JP2017503834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503834A5 JP2017503834A5 JP2016548110A JP2016548110A JP2017503834A5 JP 2017503834 A5 JP2017503834 A5 JP 2017503834A5 JP 2016548110 A JP2016548110 A JP 2016548110A JP 2016548110 A JP2016548110 A JP 2016548110A JP 2017503834 A5 JP2017503834 A5 JP 2017503834A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- clause
- clauses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 84
- 150000003839 salts Chemical class 0.000 description 66
- 125000000217 alkyl group Chemical group 0.000 description 16
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 230000002265 prevention Effects 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 6
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- -1 salts compound Chemical class 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 125000002393 azetidinyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 206010028537 myelofibrosis Diseases 0.000 description 3
- 125000003566 oxetanyl group Chemical group 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1401086.2 | 2014-01-23 | ||
| GBGB1401086.2A GB201401086D0 (en) | 2014-01-23 | 2014-01-23 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2015/050850 WO2015110378A1 (en) | 2014-01-23 | 2015-01-19 | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503834A JP2017503834A (ja) | 2017-02-02 |
| JP2017503834A5 true JP2017503834A5 (enExample) | 2018-02-22 |
| JP6472454B2 JP6472454B2 (ja) | 2019-02-20 |
Family
ID=50287405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548110A Active JP6472454B2 (ja) | 2014-01-23 | 2015-01-19 | 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9440929B2 (enExample) |
| EP (2) | EP3395802A1 (enExample) |
| JP (1) | JP6472454B2 (enExample) |
| CN (1) | CN106132934B (enExample) |
| AR (1) | AR099160A1 (enExample) |
| AU (1) | AU2015208269B2 (enExample) |
| BR (1) | BR112016016732B1 (enExample) |
| CA (1) | CA2941474A1 (enExample) |
| CY (1) | CY1120679T1 (enExample) |
| DK (1) | DK3097083T3 (enExample) |
| EA (1) | EA029827B1 (enExample) |
| ES (1) | ES2693019T3 (enExample) |
| GB (1) | GB201401086D0 (enExample) |
| HR (1) | HRP20181332T1 (enExample) |
| HU (1) | HUE039450T2 (enExample) |
| IL (1) | IL246823B (enExample) |
| LT (1) | LT3097083T (enExample) |
| MX (1) | MX370546B (enExample) |
| MY (1) | MY180363A (enExample) |
| NZ (1) | NZ723313A (enExample) |
| PH (1) | PH12016501677B1 (enExample) |
| PL (1) | PL3097083T3 (enExample) |
| PT (1) | PT3097083T (enExample) |
| SG (1) | SG11201606971XA (enExample) |
| SI (1) | SI3097083T1 (enExample) |
| TW (1) | TWI689496B (enExample) |
| WO (1) | WO2015110378A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR105400A1 (es) * | 2015-08-04 | 2017-09-27 | Lilly Co Eli | Inhibidores de jak1 |
| KR102225840B1 (ko) * | 2016-07-14 | 2021-03-11 | 일라이 릴리 앤드 캄파니 | Jak 억제제로서의 피라졸릴아미노벤즈이미다졸 유도체 |
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
| CN108355618B (zh) * | 2018-02-27 | 2020-09-08 | 江南大学 | 牛来源透明质酸酶亲和介质及其吸附方法 |
| CN108776121B (zh) * | 2018-04-08 | 2021-07-30 | 广州卡马生物科技有限公司 | 一种基于荧光猝灭原理对药材中抗氧剂的高通量筛选方法 |
| CN115215838B (zh) * | 2018-09-18 | 2025-04-04 | 拓臻股份有限公司 | 用于治疗特定白血病的化合物 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| GB201904373D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders |
| CN114671858B (zh) * | 2022-03-07 | 2023-08-08 | 华中师范大学 | 一种苯并咪唑系化合物及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008503712A (ja) | 2004-06-21 | 2008-02-07 | ガラパゴス・ナムローゼ・フェンノートシャップ | 骨関節炎治療の方法及び手段 |
| EP2226315A4 (en) * | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-aminoquinazoline DERIVATIVE |
| JP2011518219A (ja) * | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| WO2012044090A2 (ko) * | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| UY34615A (es) * | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. |
-
2014
- 2014-01-23 GB GBGB1401086.2A patent/GB201401086D0/en not_active Ceased
-
2015
- 2015-01-19 PL PL15701945T patent/PL3097083T3/pl unknown
- 2015-01-19 DK DK15701945.6T patent/DK3097083T3/en active
- 2015-01-19 EA EA201691468A patent/EA029827B1/ru not_active IP Right Cessation
- 2015-01-19 NZ NZ72331315A patent/NZ723313A/en not_active IP Right Cessation
- 2015-01-19 EP EP18177201.3A patent/EP3395802A1/en not_active Withdrawn
- 2015-01-19 CA CA2941474A patent/CA2941474A1/en not_active Abandoned
- 2015-01-19 LT LTEP15701945.6T patent/LT3097083T/lt unknown
- 2015-01-19 HU HUE15701945A patent/HUE039450T2/hu unknown
- 2015-01-19 MY MYPI2016702630A patent/MY180363A/en unknown
- 2015-01-19 BR BR112016016732-5A patent/BR112016016732B1/pt not_active IP Right Cessation
- 2015-01-19 PT PT15701945T patent/PT3097083T/pt unknown
- 2015-01-19 MX MX2016009442A patent/MX370546B/es active IP Right Grant
- 2015-01-19 ES ES15701945.6T patent/ES2693019T3/es active Active
- 2015-01-19 JP JP2016548110A patent/JP6472454B2/ja active Active
- 2015-01-19 CN CN201580015662.9A patent/CN106132934B/zh not_active Expired - Fee Related
- 2015-01-19 AU AU2015208269A patent/AU2015208269B2/en not_active Ceased
- 2015-01-19 SI SI201530383T patent/SI3097083T1/sl unknown
- 2015-01-19 HR HRP20181332TT patent/HRP20181332T1/hr unknown
- 2015-01-19 US US14/599,644 patent/US9440929B2/en active Active
- 2015-01-19 SG SG11201606971XA patent/SG11201606971XA/en unknown
- 2015-01-19 EP EP15701945.6A patent/EP3097083B1/en active Active
- 2015-01-19 WO PCT/EP2015/050850 patent/WO2015110378A1/en not_active Ceased
- 2015-01-22 AR ARP150100176A patent/AR099160A1/es unknown
- 2015-01-22 TW TW104102159A patent/TWI689496B/zh not_active IP Right Cessation
-
2016
- 2016-07-18 IL IL246823A patent/IL246823B/en active IP Right Grant
- 2016-08-23 PH PH12016501677A patent/PH12016501677B1/en unknown
- 2016-09-12 US US15/262,097 patent/US10179771B2/en active Active
-
2018
- 2018-08-23 US US16/110,353 patent/US20190152922A1/en not_active Abandoned
- 2018-09-11 CY CY181100950T patent/CY1120679T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6736559B2 (ja) | トリアゾロピリミジン化合物およびその使用 | |
| RU2018102365A (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| AU2018350980B2 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors | |
| JP2016509583A5 (enExample) | ||
| HRP20140814T1 (hr) | Inhibitori jak2 i njihova uporaba za lijeäśenje mijeloproliferativnih bolesti i karcinoma | |
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| JP2015531773A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2016519072A5 (enExample) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2017519754A5 (enExample) | ||
| CA3056833A1 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| EP3732176A1 (en) | Heterocyclic amides as kinase inhibitors | |
| WO2019226213A2 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| JP2014520108A5 (enExample) | ||
| WO2020176501A1 (en) | Compounds useful for inhibiting raf dimers | |
| JP2015502371A5 (enExample) | ||
| US11161838B2 (en) | Heterocyclic derivatives as PI3K inhibitors | |
| RU2015107426A (ru) | Пирроло[2,3-в]пиразины в качестве ингибиторов syk | |
| JP2022536655A (ja) | キナゾリニル化合物及び使用方法 | |
| ES2782113T3 (es) | Compuestos de quinolina fusionados como inhibidores de PI3K/mTor | |
| AU2019336675B2 (en) | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor | |
| JP6100755B2 (ja) | （２−ヘテロアリールアミノ）コハク酸誘導体 | |
| JP2020531486A (ja) | ピリジルピリドン化合物 | |
| RU2011136855A (ru) | Производные бензотиазолов и бензимидазолов, содержащие 6-nh-замещенные триазолопиридазинсульфанил в положении 6: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов мет | |
| HRP20170717T1 (hr) | Derivati predlijeka supstituiranih triazolopiridina |